Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 35
- Registration Number
- NCT01119781
A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 120
- Registration Number
- NCT01119677
- Locations
- 🇺🇸
Research Site, Saint Paul, Minnesota, United States
Treatment Interruption of Natalizumab
- Conditions
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 175
- Registration Number
- NCT01071083
- Locations
- 🇪🇸
Research Site, Valencia, Spain
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 35895
- Registration Number
- NCT01070836
- Locations
- 🇵🇷
Research Site, Ponce, Puerto Rico
JC-Virus (JCV) Antibody Program
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1096
- Registration Number
- NCT01070823
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 14
- Registration Number
- NCT01069913
A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis
- Conditions
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 38
- Registration Number
- NCT01065090
- Locations
- 🇦🇺
Coordinating Research Site, NSW, Australia
🇸🇪Research Site, Ängelholm, Sweden
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1841
- Registration Number
- NCT01064401
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 84
- Registration Number
- NCT01058005
- Locations
- 🇸🇪
Research Site, Molndal, Sweden
BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 72
- Registration Number
- NCT01052506
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands